UK-based Abcam, a developer and distributor of biological reagents and tools used in research, drug discovery and diagnostics, has opened a new 9,300m2 facility in Waltham, Massachusetts, US. The new site will operate as a hub for the company’s R&D and commercial activities in the region.

The facility is more than double the size of Abcam’s previous US site in the Kendall Square area of Cambridge. It is expected to eventually house 300 staff.

The opening will increase the company’s R&D, production, distribution and customer service capabilities to better serve the life sciences sector.

In a press release, chief executive officer Alan Hirzel stated: “Abcam’s first step toward global expansion was in 2003 at Kendall Square. Since then, the US has become our largest market. Investing in and expanding our presence in the vibrant Greater Boston cluster is another step in our journey to support biopharma partners and life sciences researchers globally in their quest to accelerate discovery and the translation of these discoveries into improved human health outcomes.”

The opening follows the establishment of a new cell engineering facility in Fremont, California, in December 2020.